Why the study?
Does continuous infusion of doxorubicin reduce cardiotoxicity more markedly than its antileukemic effect in vitro?
Does continuous infusion of doxorubicin reduce cardiotoxicity more markedly than its antileukemic effect in vitro?
In vitro pharmacodynamic modeling suggests continuous infusion of doxorubicin reduces cardiotoxicity more markedly than it reduces antileukemic efficacy due to a stronger dependence of cardiotoxicity on peak concentration (Cmax).
No takes yet. Share an insight, caveat, or question.
Continuous infusion may reduce doxorubicin cardiotoxicity more than antileukemic effects in vitro; leaves open clinical translation.
Kishi et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: